Aerpio Pharmaceuticals, Inc. v. Quaggin

CourtDistrict Court, S.D. Ohio
DecidedSeptember 26, 2019
Docket1:18-cv-00794
StatusUnknown

This text of Aerpio Pharmaceuticals, Inc. v. Quaggin (Aerpio Pharmaceuticals, Inc. v. Quaggin) is published on Counsel Stack Legal Research, covering District Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aerpio Pharmaceuticals, Inc. v. Quaggin, (S.D. Ohio 2019).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF OHIO WESTERN DIVISION AERPIO PHARMACEUTICALS, INC., Case No. 1:18-cv-794 Plaintiff, Dlott, J. Litkovitz, M.J. Vs. DR. SUSAN QUAGGIN, et al., REPORT AND Defendants. RECOMMENDATION Plaintiff Aerpio Pharmaceuticals, Inc. (Aerpio) brings this action against defendants Dr. Susan Quaggin, Mannin Research Inc. (Mannin), and Northwestern University Office of Sponsored Research (University). Plaintiff Aerpio brings claims for breach of contract, tortious interference with contractual relations, conversion, unjust enrichment, guantum meruit, declaratory judgment and specific performance/injunctive relief related to certain patent applications and Quaggin’s assignment of intellectual property to Mannin. This matter is before the Court on defendant Quaggin’s motion to stay litigation and compel arbitration (Doc. 29), plaintiff Aerpio’s response in opposition (Doc. 36), and Quaggin’s reply in support of the motion (Doc. 47); the University’s motion to dismiss the complaint (Doc. 32), Aerpio’s opposing memorandum (Doc. 45)’, and the University’s reply (Doc. 51); and defendant Mannin’s motion to dismiss the complaint for lack of jurisdiction or, in the alternative, to dismiss plaintiff s declaratory judgment claim as to patent application inventorship and/or stay all claims against Mannin pending arbitration between plaintiff and Quaggin (Doc. 42), Aerpio’s opposing memorandum (Doc. 49), and Mannin’s reply (Doc. 52). Aerpio moves for leave to file an omnibus surreply memorandum in opposition to defendants’ motions (Doc. 53), which defendants Quaggin, Mannin, and Northwestern oppose (Docs. 54, 55, 56).

' Aerpio has also filed an unredacted version of the memorandum under seal. (Doc. 59).

I. Factual Background Plaintiff Aerpio is a biopharmaceutical company that focuses on “advancing first-in-class treatments for eye diseases.” (Complaint, Doc. 1, § 1). Aerpio’s current lead product candidate is AKB-9778. (/d., AKB-9778 is in Phase 2b clinical trials after “an extensive pre-clinical and research program.” (/d.). Aerpio is developing AKB-9778 to treat eye diseases, including glaucoma and diabetic retinopathy. (/d.). AKB-9778 is a molecule that inhibits HPTP£, an enzyme that can disrupt the normal function of the Tie-2 receptor pathway. (/d.). Vascular endothelial protein (VE-PTP) is the “mouse homologue” of HPTPB and is therefore used as a research tool to find molecules that will inhibit HPTPB in humans. (/d.). The terms HPTPf and VE-PTP are often used interchangeably. (/d.). AKB-9778 restores the normal anatomy of diseased blood vessels at the cellular level by inhibiting VE-PTP/HPTPf and restoring the normal function of the Tie-2 receptor. (/d.). Aerpio and Quaggin began their relationship in 2011 when Quaggin and Aerpio’s predecessor-in-interest, Akebia Therapeutics, Inc. (Akebia), entered into a Unilateral Confidentiality Agreement (UCA). (/d., 43; Exh. A). The purpose of the UCA was to protect Akebia’s competitively valuable confidential information and materials, which included Tie-2 antagonists and HPTP® inhibitors, from disclosure and misuse. (/d.). In 2013, Quaggin signed a Consulting Agreement (CSA) with plaintiff Aerpio and joined its Pre-Clinical Scientific Advisory Board to provide services related to therapeutics targeted at the inhibition of HPTPB. (/d.; Exh. B). That same year, Quaggin moved from Canada and joined the University as an employee. (/d.). Aerpio and the University entered into a Material Transfer Agreement (MTA)

under which Quaggin would continue to conduct experiments as an Investigator related to the inhibition of HPTPB. (/d.; Exh. C). Aerpio alleges that under the agreements, Quaggin received samples of Aerpio’s small molecule HPTP® inhibitors, AKB-9778 and AKB-9785, and access to Aerpio’s confidential information and research and development. (/d., § 4). Aerpio alleges that on information and belief, Quaggin had never researched, had access to, or studied small molecule inhibitors of HPTPB/VE-PTP or their potential clinical use prior to her relationship with Aerpio. (/d.). Aerpio alleges that Quaggin breached each of her obligations under the CSA, which required Quaggin to disclose to Aerpio as its exclusive property all inventions, innovations, and intellectual property developed during the term of the engagement; assign all such property to Aerpio; warrant that the CSA would not interfere or conflict with any other contractual obligations; not use, publish, or disclose any confidential information without Aerpio’s prior written consent; return all information to Aerpio upon request or termination of the CSA; and treat all information obtained in the course of performing the CSA as confidential. (/d., 95). Aerpio also alleges that the University and Quaggin, acting as the University’s agent, have breached their obligations under the MTA. (/d., 96). Aerpio alleges that Quaggin and the University agreed to many of the same obligations that Quaggin agreed to under the CSA, and promised that they would: e not use Aerpio’s materials for any purpose other than the project; e not modify or reverse engineer the materials, or distribute the materials to a third party without Aerpio’s prior written consent; e keep information related to the materials and MTA confidential; e not use confidential information for any purpose other than the projects outlined in the agreement without Aerpio’s prior written consent; e provide Aerpio with a written description of an intellectual property derived from or related to Aerpio’s materials; e notify Aerpio of the University’s decision to seek or not seek patent protection on any invention;

e notify Aerpio that the University elected to not file or maintain a patent application or patent arising from an invention, giving Aerpio the right to file or maintain the application or patent at its own expense with full control over the prosecution and maintenance thereof; e provide Aerpio a first option to negotiate an exclusive license to each invention created by University inventors; and ¢ not transfer or distributor an Aerpio material or related information to any third party or individual outside of Quaggin’s laboratory without Aerpio’s prior written consent. (/d.). Aerpio alleges that it has performed all of its obligations under both the CSA and the MTA and that Quaggin has breached both agreements. (Doc. 1, 47). Aerpio claims that Quaggin violated the parties’ contractual agreements in several respects. First, Aerpio alleges that Quaggin breached the agreements and created a conflict of interest by forming a competing company, Mannin, to benefit her and her family, and by taking the position of Chief Scientific Officer with the company. (/d., 8, 9). Aerpio alleges that on information and belief, Quaggin’s position requires her to assign any intellectual property to Mannin rather than to Aerpio. (/d., 48). Aerpio claims that Quaggin has formed Mannin as a competing company using knowledge and information she learned from Aerpio, and Quaggin and Mannin are using Aerpio’s own research and knowledge to develop and research competing small molecules and biologics-based VE-PTP/HPTPf inhibitors. Aerpio alleges that Mannin now presents itself as leading the development of new vascular therapeutics and as “the ‘only company’ targeting the repair of the normal flow of fluid in the eye with a unique small molecule - presumably via VE- PTP inhibition.” (/d., J 10). Aerpio further claims that Quaggin has breached the CSA and MTA by: e submitting patent applications based on technology and information Quaggin learned from Aerpio and related to research conducted during the term of the CSA - specifically, the use of VE-PTP inhibitors to treat glaucoma and cystic kidney disease;

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hill v. G E Power Systems, Inc.
282 F.3d 343 (Fifth Circuit, 2002)
Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Buffalo Forge Co. v. United Steelworkers
428 U.S. 397 (Supreme Court, 1976)
Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
At&T Technologies, Inc. v. Communications Workers
475 U.S. 643 (Supreme Court, 1986)
First Options of Chicago, Inc. v. Kaplan
514 U.S. 938 (Supreme Court, 1995)
Ben-Kotel, Jose v. Howard Univ
319 F.3d 532 (D.C. Circuit, 2003)
Turi v. Main Street Adoption Services, LLP
633 F.3d 496 (Sixth Circuit, 2011)
Qualcomm Incorporated v. Nokia Corporation
466 F.3d 1366 (Federal Circuit, 2006)
Jewell v. Davies, U.S. District Judge
192 F.2d 670 (Sixth Circuit, 1951)
Apollo Computer, Inc. v. Helge Berg
886 F.2d 469 (First Circuit, 1989)
Javitch v. First Union Securities, Inc.
315 F.3d 619 (First Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Aerpio Pharmaceuticals, Inc. v. Quaggin, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aerpio-pharmaceuticals-inc-v-quaggin-ohsd-2019.